Status:
COMPLETED
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
Lead Sponsor:
B.P. Koirala Institute of Health Sciences
Collaborating Sponsors:
Nepal Health Research Council
Conditions:
Verruca Viral
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
Common warts are papulonodular epidermal lesions caused by human papillomavirus (HPV) usually by the strains 1, 2, 4, 27 or 57. Cutaneous warts occur in 7% to 10% of the general population, with a max...
Detailed Description
INTRODUCTION Warts are common skin conditions resulting from infection of keratinocytes by human papillomavirus (HPV). After infection of the basal layer, there is clonal proliferation leading to epid...
Eligibility Criteria
Inclusion
- 1\. Clinically diagnosed patients who have more than three warts or single wart in difficult to treat sites (periungual, palms and soles)
Exclusion
- Patients not under any systemic or topical treatment of warts for the last four weeks
- Patients with a past history of an allergic response to MMR or any other vaccine or Vitamin D
- Patients with current acute febrile illness or any bacterial infection
- Immunosuppressed patients
- Pregnant or lactating women
- Patients having a past history of asthma, allergic skin disorders or convulsions
- Patients with keloidal tendency
- Patient refusal for consent
- Treating physician's decision to give other treatment modality
- Patients with hypervitaminosis D, muscle weakness, bone pain, altered sensorium
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 30 2021
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04428359
Start Date
June 1 2020
End Date
January 30 2021
Last Update
April 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BP Koirala Institute of Health Sciences
Dharān, One, Nepal, 7053